Cardiopulmonary protection in severe respiratory disease
Disease-modifying biologic therapies have transformed long-term outcomes in patients with severe asthma and COPD: This review considers their value and the need for cardiopulmonary protection in all these patients
Learning objectives
You will learn:
- Real and potential impacts of disease-modifying biologic therapies on clinical outcomes in severe respiratory disease
- Proposed new criteria for clinical definitions of asthma remission and the efficacy of biologics that target T2/eosinophilic inflammation or epithelial alarmins in severe asthma
- Insight into cardiopulmonary risk driven by chronic obstructive pulmonary disease exacerbations and clinical/real-world evidence guiding current approaches to pharmacotherapy.
To access this module, please register or login:
